Additional JAK1/2 inhibitors, pacritinib, gandotinib, lestaurtinib, and momelotinib, are in clinical trials for myelofibrosis, myeloid neoplasms, or relapsed lymphomas, but they have not yet been investigated clinically in breast cancer patients [46,47,48,49]. Here, JAK1 is linked to lymphoma.